Morse G D, Shelton M J, Ho M, Bartos L, DeRemer M, Ragni M
Department of Pharmacy Practice, State University of New York at Buffalo 14260, USA.
Antiviral Res. 1995 Aug;27(4):419-24. doi: 10.1016/0166-3542(95)00032-h.
While the combination of zidovudine and didanosine is used in HIV-infected patients with more advanced disease, the possibility of a pharmacokinetic interaction between these two drugs remains controversial. Zidovudine doses of 50, 100, and 200 mg, combined with 67, 167, and 250 mg of didanosine were evaluated in 11 asymptomatic HIV-infected patients after receiving 24 weeks of combination therapy in AIDS Clinical Trials Group protocol 143. The pharmacokinetic parameters of zidovudine and didanosine were similar to those obtained with each drug given as monotherapy in other previously published studies. The renal clearance and urinary recovery of glucuronidated zidovudine was reduced when zidovudine was given in combination with didanosine, possibly due to competition for renal tubular secretion. These data suggest that no clinically important pharmacokinetic interaction occurs when zidovudine and didanosine are given together.
虽然齐多夫定和去羟肌苷联合用于病情更严重的HIV感染患者，但这两种药物之间药代动力学相互作用的可能性仍存在争议。在艾滋病临床试验组方案143中，对11名无症状HIV感染患者进行了为期24周的联合治疗后，评估了50、100和200毫克的齐多夫定剂量与67、167和250毫克的去羟肌苷联合使用的情况。齐多夫定和去羟肌苷的药代动力学参数与之前其他已发表研究中每种药物单药治疗时获得的参数相似。当齐多夫定与去羟肌苷联合使用时，葡萄糖醛酸化齐多夫定的肾清除率和尿回收率降低，这可能是由于肾小管分泌竞争所致。这些数据表明，齐多夫定和去羟肌苷一起使用时不会发生具有临床意义的药代动力学相互作用。
